Long term extension study of dazodalibep for Sjogren's syndrome
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study gives continued access to the study drug dazodalibep for people with Sjogren's syndrome who completed a prior phase 3 study. The goal is to see how safe and effective the medication is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished one of the earlier phase 3 studies of dazodalibep for Sjogren's syndrome.
- Your next dose of this study drug must be within 28 days of your last visit in the prior study.
- You cannot have a serious active infection that requires antibiotics or antiviral medicine.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You cannot plan to get a live vaccine during this study.
- You must be willing to use effective birth control if you are a woman who could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This study allows people who are already in a Daiichi Sankyo trial and getting benefit from the study drug to continue receiving it safely. It monitors long-term safety for those who have not had their cancer worsen.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
Hear when a new Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.